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ILLUSTRATIVE CASE
A 56-year-old patient with well-controlled 
type 2 diabetes and hypertension comes 
to see you for routine follow up. His blood 
pressure is controlled with lisinopril 
40 mg/d. But his albumin-to-creatinine ratio 
is 75 mg/g, and your records reveal that his 
albuminuria is getting progressively worse. 
 You’re aware of the potential benefi ts 
of a dual angiotensin blockade, and are 
considering adding an angiotensin receptor 
blocker (ARB) to your patient’s medication 
regimen. You wonder whether the 
combination of an angiotensin-converting 
enzyme (ACE) inhibitor and an ARB will 
slow the decline of renal function. You 
also wonder whether the combination will 
reduce your patient’s cardiovascular risk. 
ACE inhibitors are known to re-duce cardiovascular morbidity and mortality, as well as protein-
uria in patients with vascular disease or 
diabetes, whether or not they have heart 
failure.2 But few studies have compared 
the effects of ACE inhibitors and ARBs 
in high-risk patients without heart fail-
ure. Nor has there been a defi nitive study 
of the effects of an ACE inhibitor−ARB 
combination on proteinuria and cardio-
vascular risk.
❚ Are 2 drugs better than 1?
In a recent meta-analysis, researchers re-
ported that combination therapy had a 
benefi cial effect on proteinuria.3 But that 
observation was based on a small num-
ber of patients (N=309 from 10 studies), 
Avoid prescribing an angioten-
sin-converting enzyme (ACE) 
inhibitor and an angiotensin 
receptor blocker (ARB) for 
patients at high risk of vascular 
events or renal dysfunction. 
The combination does not 
reduce poor outcomes, and 
leads to more adverse drug-
related events than an ACE 
inhibitor or ARB alone.1 
Strength of recommendation 
B: 1 large, high-quality randomized controlled trial (RCT). 
The ONTARGET investigators. Telmisartan, 
ramipril, or both in patients at high risk for 
vascular events. N Engl J Med. 2008;358:
1547-1559.
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Patients on 
the combination 
had lower blood 
pressure but more 
side effects—and 
no improvement 
in key outcomes
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short follow up, and a lack of data on 
key clinical end points such as decline of 
the glomerular fi ltration rate (GFR) and 
the onset of dialysis. 
Other evidence comes from a study 
of 199 patients with diabetes and mi-
croalbuminuria, in which the ACE 
inhibitor−ARB combination reduced 
proteinuria more than either agent 
alone.4 And in a study of 336 patients 
with nondiabetic nephropathy, the 2-
drug combination slowed the decline in 
renal function more than monotherapy.5
Small studies raise hopes. These pre-
liminary fi ndings, along with the theoreti-
cal benefi ts of dual angiotensin blockade, 
suggested that the benefi ts of taking both 
agents together could be signifi cant. A 
large, well-done randomized controlled 
trial (RCT) was needed to determine the 
following: (1) whether an ARB is as ef-
fective as an ACE inhibitor in reducing 
morbidity and mortality in high-risk 
patients who don’t have heart failure, 
and (2) whether the ACE inhibitor−ARB 
combination is better than monotherapy 
for patients at high risk. 
STUDY SUMMARY
❚  Vascular outcomes same 
for ACE inhibitors, ARBs
The ONgoing Telmisartan Alone and 
in combination with Ramipril Global 
Endpoint Trial (ONTARGET), a multi-
year study of thousands of patients, ad-
dressed both of those questions. The re-
searchers compared the effects of both 
telmisartan (Micardis, an ARB) alone 
and a telmisartan + ramipril (Altace, an 
ACE inhibitor) combination with the 
effects of the ACE inhibitor alone in pa-
tients ≥55 years of age with established 
atherosclerotic vascular disease or dia-
betes with end-organ damage.1 Exclu-
sion criteria included major renal artery 
stenosis, uncorrected volume or sodium 
depletion, a serum creatinine concen-
tration of ≥3 mg/dL, and uncontrolled 
hypertension (>160 mm Hg systolic or 
>100 mm Hg diastolic). 
After a 3-week run-in period to elim-
inate those who were unable to tolerate 
either medication or were nonadherent, 
a total of 25,620 patients remained. 
They were randomly assigned to take 
The ONTARGET study:
•  established that telmisartan, 
an ARB, is not inferior to 
ramipril, an ACE inhibitor, 
in reducing cardiovascular 
and renal events in high-
risk patients without 
heart failure.
•  found that either drug alone 
is more effective than 
combination therapy for this 
patient population.
•  cast fresh doubt on the 
assumption that proteinuria 
is an accurate surrogate 
marker for progressive 
renal dysfunction. 
Key findings
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ramipril 10 mg/d, telmisartan 80 mg/d, 
or both the ACE inhibitor and the ARB. 
The researchers followed the patients for 
a median of 56 months.
The primary composite outcome 
was death from cardiovascular causes, 
myocardial infarction, stroke, or hos-
pitalization for heart failure;1 the main 
renal outcome was a composite of fi rst 
dialysis, doubling of serum creatinine, 
or death.6 
The percentage of patients with 
the primary outcome was the same in 
all 3 groups (~16.5%). This fi nding was 
somewhat surprising because the blood 
pressure of patients in the combina-
tion therapy group was 2 to 3 mm Hg 
lower overall (both systolic and diastol-
ic) than the blood pressure of patients 
on monotherapy—a difference that in 
other studies has been associated with 
an estimated 4% to 5% reduction in 
risk.1,2 Patients in the combination 
group had more hypotensive symptoms 
compared with those in the ramipril 
group (4.8% vs 1.7%, number needed 
to harm [NNH]=32, P<.001). 
Renal dysfunction was highest 
in dual therapy group 
Patients in the combination therapy 
group had higher rates of renal dys-
function than either the ramipril group 
(13.5% vs 10.2%, NNH=30, P<.001) 
or the telmisartan group (10.6%), de-
spite a decrease in proteinuria among 
those on dual therapy. Patients taking 
the 2-drug combination also had higher 
rates of hyperkalemia.
While telmisartan proved to be 
equal to ramipril in reducing vascular 
events in high-risk patients, patients 
taking the ACE inhibitor experienced 
more cough (NNH=32, P<.001) and an-
gioedema (NNH=500, P=.01). In both 
monotherapy groups, the rates of adverse 
drug reactions were probably lower than 
what we typically see in clinical practice 
because after the run-in period, only pa-
tients who were better able to tolerate 
both medications remained. 
WHAT’S NEW
❚  Combination causes 
renal impairment
This study established that telmisartan, 
an ARB, is not inferior to ramipril, an 
ACE inhibitor, in reducing cardiovascular 
and renal events in patients without heart 
failure. In addition, as the largest RCT to 
explore the effects of a dual blockade 
of the renin-angiotensin system with an 
ACE inhibitor and an ARB, it casts fresh 
doubt on the assumption that proteinuria 
is an accurate surrogate marker for pro-
gressive renal dysfunction. The reduction 
in proteinuria seen in patients in the com-
bination therapy group came at a cost of 
increased renal impairment. 
CAVEATS
❚  Findings do not apply 
to heart failure patients
More than 11% of potential subjects 
were excluded from this study during the 
run-in period. This suggests that physi-
cians in practice are likely to fi nd a signif-
icant number of patients who are unable 
to tolerate (or fail to adhere to) mono-
therapy with ACE inhibitors or ARBs. 
At baseline, only a small subgroup—
13%—had overt diabetic nephropathy, 
the hallmark for a substantial continu-
ous decline of GFR. However, 38% of 
the study group had diabetes, and al-
most 30% of these diabetes patients had 
microalbuminuria. Subgroup analysis 
found results consistent with the overall 
group, and the large sample size reduces 
the likelihood that these fi ndings were 
due to low power. The overall rate of di-
alysis and doubling of serum creatinine 
was low, but still statistically signifi cant, 
due to the large size of this study.
In determining treatment for high-risk 
patients with vascular disease or diabetes, 
it is important to keep the study popu-
lation in mind. Studies of patients with 
poorly controlled congestive heart fail-
ure (CHF) have shown potential benefi ts 
from an ACE inhibitor−ARB combina-
tion.7 The ONTARGET trial specifi cally 
The reduction 
in proteinuria 
in combination 
therapy patients 
came at a cost of 
increased renal 
impairment
PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and ﬁ ndings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
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excluded individuals with CHF, and its 
fi ndings—and recommendations to avoid 
combination therapy—should not be ap-
plied to heart failure patients. 
CHALLENGES TO IMPLEMENTATION
❚  Best microalbuminuria Tx 
remains elusive 
Although albuminuria has been consid-
ered an early sign of the onset of diabet-
ic nephropathy, the ONTARGET study 
demonstrated that combination therapy 
may cause further reduction in albumin-
uria but still adversely affect renal func-
tion. Thus, this study raises important 
questions about the best treatment for 
patients with diabetes who have micro-
albuminuria and are already on either 
an ACE inhibitor or an ARB. We won-
der, too, whether we should continue to 
test for microalbuminuria in patients 
who are taking one of these agents, giv-
en the lack of guidance regarding fur-
ther treatment. ■
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The diagnosis and management of psychotic and mood disorders is an evolv-ing process and an important clinical topic for primary care clinicians (PCPs). 
Although many reports exist on the prevalence and treatment of depression in pri-
mary care, far less information is available about patients in this setting with depres-
sion accompanied by symptoms of mania or hypomania.1
To facilitate a dialogue on the identifi cation and treatment of psychotic and 
mood disorders, we invited 4 expert faculty members to present actual patient cases 
followed by a panel discussion in which the collective experience of all the faculty 
lends further practical insights into the nuances of management of such patients 
in both inpatient and outpatient settings. In particular, these cases underscore the 
importance of being alert to critical clues in a patient’s history or the family’s history. 
A larger version of this panel discussion appears in a supplement to the December 
2008 issue of CURRENT PSYCHIATRY. We’ve extracted the portion that we felt would be 
of most interest to primary care providers.
The case selected for presentation here is by David Muzina, MD, and concerns 
a 20-year-old man who was referred for psychiatric evaluation by his PCP and psy-
chologist for treatment of mood swings, anxiety, and confusion. He had been given 
sertraline and then venlafaxine, but discontinued both medications on his own. His 
symptoms began rather abruptly 14 months earlier, coinciding with an intense pro-
gram of weight lifting and supplement use to change his self-described smallness. 
Profound, persistent sadness and feeling “dead inside” were his chief complaints, 
and they had led to a break-up with his girlfriend, which distressed him greatly and 
preoccupied his thinking. He also believed his parents were hiding from him the 
truth of a signifi cant birth defect.
Following the case presentation is a faculty discussion of several pivotal issues 
in the management of mood disorders:
• Pitfalls to avoid during the diagnostic evaluation
• Pros and cons of monotherapy and combination therapy
•  Mechanisms of action of available medications and implications for an eff ec-
tive treatment plan
•  Suggestions for enabling patient compliance with prescribed regimens
We hope the insights you glean from this exchange of practical clinical issues 
will enhance and confi rm your own approach to diagnosing and treating patients 
with psychotic and mood disorders.
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•  Understand the mechanisms of action, hepatic eff ects, and other 
metabolic eff ects of available agents and their potential impact on 
treatment
•  Develop an eff ective treatment plan that includes monotherapy or 
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ment to meet individual patient needs
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